Dotarizin
 | |
| IUPAC ime | |
|---|---|
1-[difenilmetil]-4-[3-(2-fenil-1,3-dioksolan-2-il)propil]piperazin | |
| Identifikatori | |
| CAS broj | 84625-59-2  |
| ATC kod | none |
| PubChem | CID 55285 |
| UNII | IO7663S6D3 |
| Sinonimi | Dotarizine |
| Hemijski podaci | |
| Formula | C29H34N2O2 |
| Molarna masa | 442,592 g/mol |
| |
Dotarizin je lek koji se koristi za tretman migrene.[1] On deluje kao blokator kalcijumovog kanala,[2] antagonist 5HT2A receptora, i u manjoj meri 5HT1A i 5HT2C receptora.[3][4] On ima antimigrenski efekat jer deluje kao vazodilatator,[5][6] i zato što ima izvesno anksiolitičko dejstvo.[7] Dotarizin blokira amneziju proizvedenu elektrokonvulzivnim šokom kod životinja.[8]
Reference
[уреди | уреди извор]- ^ Ruiz-Nuño, A; Villarroya, M; Cano-Abad, M; Rosado, A; Balfagón, G; López, MG; García, AG (2001). „Mechanisms of blockade by the novel migraine prophylactic agent, dotarizine, of various brain and peripheral vessel contractility”. European Journal of Pharmacology. 411 (3): 289—99. PMID 11164387. doi:10.1016/S0014-2999(00)00897-9.
- ^ Ruiz-Nuño, A; Mayorgas, I; Hernández-Guijo, JM; Olivares, R; García, AG; Gandía, L (2003). „Antimigraine dotarizine blocks P/Q Ca2+ channels and exocytosis in a voltage-dependent manner in chromaffin cells”. European Journal of Pharmacology. 481 (1): 41—50. PMID 14637173. doi:10.1016/j.ejphar.2003.09.013.
- ^ Farré, M; Roset, PN; Llorente, M; Márquez, M; Albet, C; Pérez, JA; Herrero, E; Ortíz, JA (1997). „Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration”. Methods and findings in experimental and clinical pharmacology. 19 (5): 343—50. PMID 9379783.
- ^ Montiel, C; Herrero, CJ; García-Palomero, E; Renart, J; García, AG; Lomax, RB (1997). „Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT2 receptors”. European Journal of Pharmacology. 332 (2): 183—93. PMID 9286620. doi:10.1016/S0014-2999(97)01073-X.
- ^ Kuridze, N; Gajkowska, B; Czernicki, Z; Jurkiewicz, J; Cervos-Navarro, J (1998). „The effect of Dotarizine--(Ca2+ channel blocker)--on vascular reactivity and ultrastructure of cerebral capillaries in animals subjected to anoxia”. Folia neuropathologica / Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences. 36 (2): 101—8. PMID 9757621.
- ^ Kuridze, N; Czernicki, Z; Jarus-Dziedzic, K; Jurkiewicz, J; Cervos-Navarro, J (2000). „Regional differences of cerebrovascular reactivity effected by calcium channel blocker - dotarizine”. Journal of the neurological sciences. 175 (1): 13—6. PMID 10785251. doi:10.1016/S0022-510X(00)00275-6.
- ^ Petkov, VD; Belcheva, S; Konstantinova, E (1995). „Anxiolytic effects of dotarizine, a possible antimigraine drug”. Methods and findings in experimental and clinical pharmacology. 17 (10): 659—68. PMID 9053586.
- ^ Lazarova, M; Petkova, B; Petkov, VD (1995). „Effect of dotarizine on electroconvulsive shock or pentylenetetrazol-induced amnesia and on seizure reactivity in rats”. Methods and findings in experimental and clinical pharmacology. 17 (1): 53—8. PMID 7623521.
